Fierce Pharma Asia—China's new NRDL; Biocon-Viatris biosimilar merger?; Avistone's $200M series A

Big Pharma's cancer immunotherapies were once again excluded from China's national reimbursement. Biocon and Viatris are reportedly considering combining their biosimilar operations. A Chinese oncology biotech just secured a handsome $200 million series A. And more.

Related Keywords

China ,United States ,Chinese ,American ,Brii Bioscience ,Eli Lilly ,Pfizer ,Avistone Pharmaceuticals ,Biocon ,Syntegon Technology ,Spinraza ,Escarta Axicabtagene Ciloleucel ,Viatris ,Shanghai Fosun Pharmaceutical Group ,Shanghai Pharmaceutical ,Aslan Pharmaceuticals ,Iqvia ,Drug Reimbursement ,Drug Prices ,Pd 1 L1 ,Immuno Oncology ,Biosimilar ,M Amp A ,Venture Capital ,Complete Response Letter ,Covid 19 ,Antibody Drugs ,Drug Approval ,Manufacturing ,Eczema ,Pharma ,